{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glimepiride+placebo", "query": { "intervention": "glimepiride placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glimepiride+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T00:36:29.537Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01496443", "title": "TAK-875 Glimepiride Drug-Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "TAK-875 and Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "68 Years", "sex": "ALL", "summary": "18 Years to 68 Years" }, "enrollment_count": 28, "start_date": "2012-01", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-09-13", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496443" }, { "nct_id": "NCT01087502", "title": "Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Linagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2010-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 16, "location_summary": "Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087502" }, { "nct_id": "NCT01829477", "title": "Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "TAK-875", "type": "DRUG" }, { "name": "TAK-875 Placebo", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2013-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 38, "location_summary": "Muscle Shoals, Alabama • Phoenix, Arizona • Fresno, California + 35 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829477" }, { "nct_id": "NCT00740051", "title": "A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Linagliptin", "type": "DRUG" }, { "name": "Linagliptin Placebo", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 227, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Greenbrae, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Harbor City", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00740051" }, { "nct_id": "NCT02769481", "title": "Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Bexagliflozin", "type": "DRUG" }, { "name": "Placebo for Bexagliflozin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo for Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theracos", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 426, "start_date": "2016-08-15", "completion_date": "2019-06-14", "has_results": true, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Carlos", "state": "California" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02769481" }, { "nct_id": "NCT00225264", "title": "Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "45 Years to 85 Years" }, "enrollment_count": 458, "start_date": "2003-10", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2012-02-28", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225264" }, { "nct_id": "NCT01243424", "title": "CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "linagliptin", "type": "DRUG" }, { "name": "glimepiride", "type": "DRUG" }, { "name": "linagliptin placebo", "type": "DRUG" }, { "name": "glimepiride placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 6103, "start_date": "2010-11-11", "completion_date": "2018-08-21", "has_results": true, "last_update_posted_date": "2020-01-07", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 177, "location_summary": "Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243424" }, { "nct_id": "NCT02419612", "title": "A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 444, "start_date": "2015-08-14", "completion_date": "2019-09-18", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419612" }, { "nct_id": "NCT01517373", "title": "Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04937319 10 mg", "type": "DRUG" }, { "name": "PF-04937319 50 mg", "type": "DRUG" }, { "name": "PF-04937319 100 mg", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 304, "start_date": "2012-02", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 23, "location_summary": "Roseville, California • San Diego, California • Walnut Creek, California + 17 more", "locations": [ { "city": "Roseville", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517373" }, { "nct_id": "NCT01769378", "title": "Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2013-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-01-25", "last_synced_at": "2026-09-20T00:36:29.537Z", "location_count": 6, "location_summary": "Chino, California • Miami, Florida • St Louis, Missouri + 3 more", "locations": [ { "city": "Chino", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Trenton", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769378" } ] }